2. Academic Validation
  3. BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia

BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia

  • ACS Med Chem Lett. 2017 Feb 8;8(3):366-371. doi: 10.1021/acsmedchemlett.7b00032.
Dalton King 1,  Christiana Iwuagwu 1,  Jim Cook 1,  Ivar M McDonald 1,  Robert Mate 1,  F Christopher Zusi 1,  Matthew D Hill 1,  Haiquan Fang 1,  Rulin Zhao 1,  Bei Wang 1,  Amy E Easton 1,  Regina Miller 1,  Debra Post-Munson 1,  Ronald J Knox 1,  Lizbeth Gallagher 1,  Ryan Westphal 1,  Thaddeus Molski 1,  Jingsong Fan 1,  Wendy Clarke 1,  Yulia Benitex 1,  Kimberley A Lentz 1,  Rex Denton 1,  Daniel Morgan 1,  Robert Zaczek 1,  Nicholas J Lodge 1,  Linda J Bristow 1,  John E Macor 1,  Richard E Olson 1
Affiliations

Affiliation

  • 1 Research and Development, Bristol-Myers Squibb , 5 Research Parkway, Wallingford, Connecticut 06492, United States.
PMID: 28337332 DOI: 10.1021/acsmedchemlett.7b00032
Abstract

The therapeutic treatment of negative symptoms and cognitive dysfunction associated with schizophrenia is a significant unmet medical need. Preclinical literature indicates that α7 neuronal nicotinic acetylcholine (nACh) receptor agonists may provide an effective approach to treating cognitive dysfunction in schizophrenia. We report herein the discovery and evaluation of 1c (BMS-933043), a novel and potent α7 nACh receptor partial agonist with high selectivity against Other nicotinic acetylcholine receptor subtypes (>100-fold) and the 5-HT3A receptor (>300-fold). In vivo activity was demonstrated in a preclinical model of cognitive impairment, mouse novel object recognition. BMS-933043 has completed Phase I clinical trials.

Keywords

Schizophrenia; clinical candidate; quinuclidine; α7 nAChR partial agonist; α7 neuronal nicotinic acetylcholine receptor.

Figures
Products